Back
Compare AU
Compare XMET vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Critical Minerals ETF (XMET) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
XMET | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 237 | 82 |
Median incremental investment | $1,003.11 | $678.72 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,483.02 | $2,220.40 |
Average age group | > 35 | > 35 |
Key Summary
XMET | CURE | |
|---|---|---|
Strategy | XMET.AX was created on 2022-10-26 by BetaShares. The fund's investment portfolio concentrates primarily on materials equity. The investment objective of the Fund is to provide an investment return that aims to track the performance of the Nasdaq Sprott Energy Transition Materials Select Index, before taking into account fees and expenses | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | KRW - KOREAN WON (0 %) ANGLO AMERICAN PLC (5.74 %) TECK RESOURCES LTD (5.58 %) | Moderna Inc (2.18 %) Twist Bioscience Corp (1.87 %) Natera Inc (1.81 %) |
Top 3 industries | Other (54.19 %) Materials (45.78 %) Industrials (0.07 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | Canada (38.24 %) Australia (22.07 %) United States (16.46 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0.69 % | 0.45 % |
Key Summary
XMET | CURE | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | Nasdaq Sprott Energy Transition Materials Select Index - AUD - Benchmark TR Net | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.69 % | 0.45 % |
Price | $13.86 | $72.80 |
Size | $133.031 million | $47.072 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.15 % | 0.03 % |
Market | ASX | ASX |
First listed date | 27/10/2022 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
XMET | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 237 | 82 |
Median incremental investment | $1,003.11 | $678.72 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,483.02 | $2,220.40 |
Average age group | > 35 | > 35 |
Pros and Cons
XMET | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
XMET | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |